Trial Profile

A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimekizumab (Primary)
Indications Hidradenitis suppurativa
Focus Adverse reactions
Acronyms BE HEARD EXTENSION
Sponsors UCB Biopharma

Most Recent Events

07 Mar 2025 Results presented in the UCB media release.
07 Mar 2025 According to an UCB media release, pooled data from the BE HEARD I&II studies and BE HEARD EXT study, presented at the AAD 2025.
12 Feb 2025 According to an UCB media release, Further results from BE HEARD EXT evaluating the efficacy and safety profile of bimekizumab will be presented later this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com